Literature DB >> 16121334

Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1.

Sergei A Moshkovskii1, Marina V Serebryakova, Konstantin B Kuteykin-Teplyakov, Olga V Tikhonova, Eugene I Goufman, Victor G Zgoda, Irina N Taranets, Oleg V Makarov, Alexander I Archakov.   

Abstract

In this study, to reduce the number of major plasma components, we examined thermostable plasma fractions to search for a biomarker of ovarian cancer. An apparent cancer biomarker of 11.7 kDa was detected in these fractions using ProteinChip SELDI-TOF mass spectrometry system. This peak invariably appeared with another close peak of about 11.5 kDa, suggesting that it is a derivative of a larger mass molecule. Of 27 cancer plasma specimens, 15 (55.6%) demonstrated this peak pair, whereas only 2 of 34 controls specimens (5.8%) were shown to express it with low intensity. Using a method involving cysteine modification by 4-vinylpyridine (4-VP), 2-DE and HPLC, these peaks were identified by mass spectrometry as serum amyloid A1 (11.68 kDa) and its N-terminal arginine-truncated form (11.52 kDa).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16121334     DOI: 10.1002/pmic.200401205

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  34 in total

1.  Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors.

Authors:  Jiaxiang Wang; Lei Wang; Da Zhang; Yuxia Fan; Zhankui Jia; Pan Qin; Jiekai Yu; Shu Zheng; Fuquan Yang
Journal:  Mol Biol Rep       Date:  2011-12-08       Impact factor: 2.316

Review 2.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

3.  An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring.

Authors:  Rachel A Egler; Yiting Li; Tu Anh T Dang; Tricia L Peters; Eastwood Leung; Shixia Huang; Heidi V Russell; Hao Liu; Tsz-Kwong Man
Journal:  Proteomics Clin Appl       Date:  2011-09-07       Impact factor: 3.494

4.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

Review 5.  Proteomic technology for biomarker profiling in cancer: an update.

Authors:  Moulay A Alaoui-Jamali; Ying-jie Xu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

6.  Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range.

Authors:  Christine L Gatlin-Bunai; Lisa H Cazares; William E Cooke; Oliver J Semmes; Dariya I Malyarenko
Journal:  J Proteome Res       Date:  2007-10-05       Impact factor: 4.466

7.  Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

Authors:  Alfonso Bellacosa; Andrew K Godwin; Suraj Peri; Karthik Devarajan; Elena Caretti; Lisa Vanderveer; Betsy Bove; Carolyn Slater; Yan Zhou; Mary Daly; Sharon Howard; Kerry S Campbell; Emmanuelle Nicolas; Anthony T Yeung; Margie L Clapper; James A Crowell; Henry T Lynch; Eric Ross; Levy Kopelovich; Alfred G Knudson
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum.

Authors:  Kristin Lm Boylan; John D Andersen; Lorraine B Anderson; LeeAnn Higgins; Amy Pn Skubitz
Journal:  Proteome Sci       Date:  2010-06-14       Impact factor: 2.480

9.  Serum amyloid A: A new potential serum marker correlated with the stage of breast cancer.

Authors:  Guojun Zhang; Xudong Sun; Hong Lv; Xiaolin Yang; Xixiong Kang
Journal:  Oncol Lett       Date:  2012-01-30       Impact factor: 2.967

10.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.